Just a handful of years ago, malignant melanoma was a diagnosis with few treatment options. Oncologists had no obvious roadmap for this perilous disease and were forced to explore beyond targeted therapies and chemotherapy.
Of Interest
Melanoma Immunotherapy Resistance Reversed by Blocking HPGDS
A new study led by Max Mazzone, professor at the VIB-KU Leuven Center for Cancer Biology identifies the enzyme hematopoietic prostaglandin D synthase (HPGDS) as a key driver of immunotherapy resistance in melanoma. Published in Cancer Discovery, the findings highlight that targeting HPGDS can reprogram tumor-associated macrophages (TAMs) and sensitize tumors to immune checkpoint blockade therapies, offering a promising new strategy for patients who currently fail to respond.
Unlocking Melanoma Immunotherapy Resistance: New Clues from T-Cell Plasticity
A new study offers clues to overcoming one of the most stubborn challenges in cancer treatment: resistance to immunotherapy. By examining both mouse models and clinical data from melanoma patients, the research team from Memorial Sloan Kettering Cancer Center (MSKCC) and the Earle A. Chiles Research Institute in Oregon has uncovered immune signatures that may help predict who will respond to a new combination immunotherapy—and why.
Discovery reveals protein involved in Parkinson’s disease also drives skin cancer
A small protein involved in neurodegeneration leading to Parkinson’s disease also drives a type of skin cancer known as melanoma, new research led by Oregon Health & Science University finds.